Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients (eReach)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04353973
Recruitment Status : Recruiting
First Posted : April 21, 2020
Last Update Posted : October 20, 2021
Sponsor:
Collaborators:
AstraZeneca
Fox Chase Cancer Center
Basser Center for BRCA
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.

Condition or disease Intervention/treatment Phase
Cancer Other: Pre-Test Intervention Other: Standard of Care Other: Post-Test Intervention Not Applicable

Detailed Description:

Cancer genetic testing has become a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With FDA approval for PARP inhibitors in patients with advanced breast, ovarian, pancreatic and prostate cancer, there is an additional therapeutic rationale for testing all breast, ovarian, pancreatic and prostate cancer patients for germline genetic mutations. Yet, access to genetic specialists is limited in many area, and the traditional model of pre- and post-test counseling with a genetic professional will not support the rising indications for cancer genetic testing. Thus, there is an urgent need to consider alternative delivery models to increase access and uptake of testing, while maintaining adequate patient outcomes.

This study aims to assess if traditional pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor can be replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver cancer genetic testing in patients with breast, ovarian, pancreatic and prostate cancer, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.

Specific Aim 1: To determine if web-based eHealth delivery of pre-test and/or post-test counseling can provide equal or improved cognitive and affective short-term and 6-month outcomes as compared to the two-visit standard of care delivery model with a genetic counselor. The investigator's primary outcomes will be changes in knowledge and anxiety. Secondary outcomes will include uptake of testing, depression, cancer specific distress, uncertainty and health behaviors and provider time.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 560 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
Actual Study Start Date : August 17, 2020
Estimated Primary Completion Date : January 1, 2023
Estimated Study Completion Date : January 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genetic Testing

Arm Intervention/treatment
Experimental: ARM A

Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

Other: Standard of Care
Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

Experimental: ARM B

Visit 1/Pre-Test Session - Standard-of-Care Pre-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.

Other: Standard of Care
Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

Other: Post-Test Intervention
Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Experimental: ARM C

Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.

Visit 2/Disclosure Session - Standard-of-Care Post-Test Counseling with a genetic counselor either in-person or by remote services (Telephone or Video Conferencing).

Other: Pre-Test Intervention
Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Other: Standard of Care
Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

Experimental: ARM D

Visit 1/Pre-Test Session - Self-directed web-based eHealth pre-test session intervention.

Visit 2/Disclosure Session - Self-directed web-based eHealth result disclosure intervention.

Other: Pre-Test Intervention
Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Other: Post-Test Intervention
Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.




Primary Outcome Measures :
  1. Change in Knowledge [ Time Frame: Baseline - Within 7 days of Visit 2 ]
    Knowledge Scale - Score Range = 0-16 Increased change score indicates increase in knowledge (better).

  2. Change in Anxiety [ Time Frame: Baseline - Within 7 days of Visit 2 ]
    Patient-Reported Outcomes Measurement Information Systems (PROMIS) - Score Range = 4-20 Decreased score change indicates a decrease in anxiety (better).


Secondary Outcome Measures :
  1. Change in Depression [ Time Frame: Baseline - Within 7 days of Visit 2 ]
    Patient-Reported Outcomes Measurement Information System (PROMIS) - Score Range = 4-20 Decreased score change indicates a decrease in depression (better).

  2. Change in Cancer Specific Distress [ Time Frame: Baseline - Within 7 days of Visit 2 ]
    Impact of Events Scale (IES) - Score Range = 0-40 Decreased score change indicates a decrease in distress (better).

  3. Change in Uncertainty [ Time Frame: Within 7 days of Visit 2 - 6-Month Follow-Up ]
    Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA) - Score Range = 0-85 Decrease in score change indicates a decrease in uncertainty (better).

  4. Change in Health Behaviors [ Time Frame: Within 7 days of Visit 2 - 6-Month Follow-Up ]
    Change in treatment plan and communication of results - Yes/No

  5. Provider Time [ Time Frame: Within 7 days of Standard of Care V1 ]
    Time (minutes) provider spends per study participant

  6. Provider Time [ Time Frame: Within 7 days of Standard of Care V2 ]
    Time (minutes) provider spends per study participant

  7. Frequency of Uptake of Testing [ Time Frame: Within 7 days of Visit 1 ]
    Testing uptake per arm - Yes/No



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Speak and understand English
  • Male or Female
  • A personal history of one or more of the following:

    • metastatic breast cancer
    • advanced ovarian cancer (Stage III-IV)
    • metastatic pancreatic cancer
    • metastatic prostate cancer
  • Naive to previous cancer germline genetic testing

Exclusion Criteria:

  • Communication difficulties such as:

    • Uncorrected or uncompensated hearing and/or vision impairment
    • Uncorrected or uncompensated speech defects
    • Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04353973


Contacts
Layout table for location contacts
Contact: Angela R Bradbury, MD 215 615 3341 Angela.Bradbury@pennmedicine.upenn.edu
Contact: Dominique Fetzer, BA 215 662 2753 Dominique.Fetzer@pennmedicine.upenn.edu

Locations
Layout table for location information
United States, Pennsylvania
Abramson Cancer Center at University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Angela Bradbury, MD       Angela.Bradbury@uphs.upenn.edu   
Principal Investigator: Angela Bradbury, MD         
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
AstraZeneca
Fox Chase Cancer Center
Basser Center for BRCA
Merck Sharp & Dohme LLC
Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT04353973    
Other Study ID Numbers: UPCC 11919
IRB#833370 ( Other Identifier: University of Pennsylvania IRB )
First Posted: April 21, 2020    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease Susceptibility
Disease Attributes
Pathologic Processes